Report

Update: Termination of coverage

Edison Investment Research is terminating coverage on LeMaitre Vascular (LMAT). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Underlying
LeMaitre Vascular Inc.

LeMaitre Vascular is a provider of medical devices and human tissue cryopreservation services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons. The company's portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and includes the LeMaitre valvulotome, the XenoSure biologic patch, the Pruitt F3 carotid shunt, VascuTape radiopaque tape, and Syntel embolectomy catheters. The company's principal product offerings are sold throughout the world, primarily in the United States, Europe and Asia/Pacific Rim.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch